CPH-I and HE4 Are More Favorable Than CA125 in Differentiating Borderline Ovarian Tumors from Epithelial Ovarian Cancer at Early Stages
Table 2
Comparison of HE4, CA125, ROMA, and CPH-I in different groups.
Benign
BOT I+II
EOC I+II
All
Pre-M
Post-M
All
Pre-M
Post-M
All
Pre-M
Post-M
HE4 (pmol/L)
43.8 (39.2-49.1)
43.9 (38.9-49.1)
43.5 (41.5-55.9)
48.4 (41.8-56.5)
47.6 (41.2-56.0)
50.1 (45.4-61.4)
80.3 (55.3-171.2)^
64.2 (50.7-136.4)^
95.0 (67.4-221.0)^
CA125 (U/mL)
24.9 (15.2-55.0)
25.3 (16.2-61.0)
13.6 (10.5-33.7)
34.1 (19.5-69.0)
35.6 (21.5-67.3)#
22.2 (16.9-189.8)
95.1 (35.6-234.5)^
88.5 (35.7-182.1)^
104.5 (33.4-320.7)
ROMA (%)
6.03 (4.5-8.0)
5.7 (4.4-7.4)
11.5 (8.1-16.5)
7.5 (5.3-12.0)
6.7 (5.1-10.3)
15.4 (11.7-56.5)
30.7 (10.6-65.6)^
14.6 (8.7-49.5)^
59.7 (28.6-81.5)^
CPH-I (%)
1.0 (0.7-2.3)
1.0 (0.7-2.2)
1.8 (0.9-2.5)
1.6 (0.9-3.1)
1.4 (0.9-2.8)#
2.3 (1.4-16.1)
11.3 (3.3-42.6)^
7.2 (2.3-26.0)^
25.1 (7.4-59.9)^
Note: data are presented as the median (interquartile range). and # compared with benign corresponding subgroups; ^ compared with BOT I+II corresponding subgroups. Abbreviations: Pre-M = premenopausal; Post-M = postmenopausal; BOT I+II = borderline ovarian tumors in FIGO stages I and II; EOC I+II = epithelial ovarian cancer in FIGO stages I and II.